Lilly Expands Gate Bioscience Deal to Over $870 Million
Lilly adds a target to its Gate Bioscience molecular gates collaboration, with total potential value above $870M. What is and is not disclosed.
CSL Alentis Partnership: $1.6B Lixudebart Deal Explained
CSL pays $355M upfront in a partnership with Alentis to co-develop lixudebart for rare kidney and liver diseases, worth up to about $1.6B.